<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169061</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14084113</org_study_id>
    <nct_id>NCT04169061</nct_id>
  </id_info>
  <brief_title>Impact of Acthar on Everyday Life of Participants With Severe Keratitis</brief_title>
  <official_title>A Multicenter, Open-label Study to Assess the Efficacy and Safety of ActharÂ® Gel in Subjects With Severe Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will need about 36 participants for this study.

      Volunteers might be able to participate if:

        -  they have bad noninfectious keratitis

        -  early treatments failed or were not well accepted

      Participants will be in the study for about 22 weeks:

        -  4 weeks for tests to see if the study might be good for them

        -  12 weeks of treatment with Acthar gel

        -  4 weeks to wean off Acthar gel and follow-up with the doctor
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder scores on the IDEEL questionnaire</measure>
    <time_frame>within 88 days</time_frame>
    <description>The Impact of Dry Eye on Everyday Life (IDEEL) questionnaire is made up of 57 questions divided into 3 sections. Each section is scored from 0 to 100; a higher score in the first two 2 sections means quality of life and treatment satisfaction got better, but a higher score in the third section means the symptoms of dry eye got more bothersome (so a lower score in that section is better). The highest possible score is 300, but the best possible score is 200.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Keratitis</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive:
a shot of Acthar (80 units) under the skin twice a week for 12 weeks
a shot of Acthar (40 units) twice a week for 2 weeks
a shot of Acthar (40 units) once a week for 2 more weeks
At each visit they will have medical tests and answer questions about their symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>Acthar gel for subcutaneous injection</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>Acthar Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has severe or recalcitrant keratitis

          -  Did not respond to, or tolerate, treatment with topical cyclosporine or any
             immunosuppressant to treat keratitis

          -  If able to reproduce, agrees to use 2 forms of effective contraception with a partner
             of the opposite sex for the duration of the study (through Visit 6)

          -  Has normal eyelids, and protocol-defined physical and medical eye attributes

          -  Agrees to avoid wearing contact lenses during the trial

        Exclusion Criteria:

          -  Is pregnant or breast-feeding

          -  Is defined as vulnerable, or is employed by, or related to anyone involved in the
             study

          -  Has a medical condition or history that might, per protocol or in the opinion of the
             investigator, compromise the participant's safety or study analysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information Call Center</last_name>
    <phone>800-556-3314</phone>
    <phone_ext>5</phone_ext>
    <email>clinicaltrials@mnk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cornea and Cataract Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>602-258-4342</phone>
      <email>ccazresearch@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Research Management, Inc.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>01204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Care Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>502-589-1500</phone>
      <email>kjohnson@eyecareinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Raynham</city>
        <state>Massachusetts</state>
        <zip>02767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>978-685-8900</phone>
      <email>kkeohane@oraclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vita Eye Clinic</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>704-487-4099</phone>
      <email>annamhall91@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates, PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>06066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>724-772-3000</phone>
      <email>nhindman@scottandchristie.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, P.A.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Advancing Vision Research, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-502-2871</phone>
      <phone_ext>102</phone_ext>
      <email>meganm@avrteam.com; brandiw@avrteam.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe or recalcitrant keratitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

